09:39 AM EST - Antibe Therapeutics Inc. : Announced Health Canada’s approval to initiate the pharmacokinetic/pharmacodynamic study of otenaproxesul’s faster-absorbing formulation for acute pain. Set to commence in October, the purpose of the study is to inform the doses for the Phase II trial. Antibe Therapeutics Inc.
shares T.ATE are trading unchanged at $0.47.
